BLOOD 2021: The Next-Generation Hypomethylator Guadecitabine Conveys a High Rate of Disease Control With Acceptable Toxicity in PTCL
RHOA mutations correlated with improved PFS.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.